Researchers at Stanford University's Curtis Laboratory have used gene expression to categorize the sensitivity and resistance of anthracycline chemotherapy in breast cancer patients with utmost precision.
Researchers at Stanford have leveraged spatial proteomic analysis to identify biomarkers with immediate implications for HER2-positive breast cancer treatment decision making and patient stratification.
Researchers at Stanford have developed methods of diagnosing and treating colorectal cancer based on the discovery of genetic aberrations indicative of a patient's risk of metastasis.
Stanford researchers have formulated a statistical model to determine the risk of breast cancer recurrence with unprecedented accuracy in women 5 – 20 years after initial diagnosis.